The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Marieke E. Straver; Annuska M. Glas; Juliane Hannemann; Jelle Wesseling; Marc J. Van De Vijver; Emiel J.Th Rutgers; Marie Jeanne T.F.D. Vrancken Peeters; Harm Van Tinteren; Laura J. Van'T Veer; Sjoerd Rodenhuis

doi:10.1007/s10549-009-0333-1

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Marieke E. Straver, Annuska M. Glas, Juliane Hannemann, Jelle Wesseling, Marc J. Van De Vijver, Emiel J.Th Rutgers, Marie Jeanne T.F.D. Vrancken Peeters, Harm Van Tinteren, Laura J. Van'T Veer, Sjoerd Rodenhuis

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

221 Citaten (Scopus)

Samenvatting

The 70-gene signature (MammaPrint™) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II-III patients prior to neoadjuvant chemotherapy and classified the prognosis-signatures. Pathological complete remission (pCR) was used to measure chemosensitivity. Among 167 patients, 144 (86%) were having a poor and 23 (14%) a good prognosis-signature. None of the good prognosis-signature patients achieved a pCR (0/23), whereas 29/144 patients (20%) in the poor prognosis-signature group did (P = 0.015). All triple-negative tumors (n = 38) had a poor prognosis-signature. Within the non triple-negative subgroup, the response of the primary tumor remained associated with the classification of the prognosis-signature (P = 0.023). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy.

Originele taal-2	Engels
Pagina's (van-tot)	551-558
Aantal pagina's	8
Tijdschrift	Breast Cancer Research and Treatment
Volume	119
Nummer van het tijdschrift	3
DOI's	https://doi.org/10.1007/s10549-009-0333-1
Status	Gepubliceerd - feb. 2010
Extern gepubliceerd	Ja

Toegang tot document

10.1007/s10549-009-0333-1

Citeer dit

Straver, M. E., Glas, A. M., Hannemann, J., Wesseling, J., Van De Vijver, M. J., Rutgers, E. J. T., Vrancken Peeters, M. J. T. F. D., Van Tinteren, H., Van'T Veer, L. J., & Rodenhuis, S. (2010). The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment, 119(3), 551-558. https://doi.org/10.1007/s10549-009-0333-1

@article{af45bb75fea04aa9b28c5c43f2a70f64,

title = "The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer",

abstract = "The 70-gene signature (MammaPrint{\texttrademark}) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II-III patients prior to neoadjuvant chemotherapy and classified the prognosis-signatures. Pathological complete remission (pCR) was used to measure chemosensitivity. Among 167 patients, 144 (86\%) were having a poor and 23 (14\%) a good prognosis-signature. None of the good prognosis-signature patients achieved a pCR (0/23), whereas 29/144 patients (20\%) in the poor prognosis-signature group did (P = 0.015). All triple-negative tumors (n = 38) had a poor prognosis-signature. Within the non triple-negative subgroup, the response of the primary tumor remained associated with the classification of the prognosis-signature (P = 0.023). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy.",

keywords = "Breast cancer, Chemosensitivity, Gene expression signature, Neoadjuvant, Predictive",

author = "Straver, \{Marieke E.\} and Glas, \{Annuska M.\} and Juliane Hannemann and Jelle Wesseling and \{Van De Vijver\}, \{Marc J.\} and Rutgers, \{Emiel J.Th\} and \{Vrancken Peeters\}, \{Marie Jeanne T.F.D.\} and \{Van Tinteren\}, Harm and \{Van'T Veer\}, \{Laura J.\} and Sjoerd Rodenhuis",

year = "2010",

month = feb,

doi = "10.1007/s10549-009-0333-1",

language = "English",

volume = "119",

pages = "551--558",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

AU - Straver, Marieke E.

AU - Glas, Annuska M.

AU - Hannemann, Juliane

AU - Wesseling, Jelle

AU - Van De Vijver, Marc J.

AU - Rutgers, Emiel J.Th

AU - Vrancken Peeters, Marie Jeanne T.F.D.

AU - Van Tinteren, Harm

AU - Van'T Veer, Laura J.

AU - Rodenhuis, Sjoerd

PY - 2010/2

Y1 - 2010/2

N2 - The 70-gene signature (MammaPrint™) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II-III patients prior to neoadjuvant chemotherapy and classified the prognosis-signatures. Pathological complete remission (pCR) was used to measure chemosensitivity. Among 167 patients, 144 (86%) were having a poor and 23 (14%) a good prognosis-signature. None of the good prognosis-signature patients achieved a pCR (0/23), whereas 29/144 patients (20%) in the poor prognosis-signature group did (P = 0.015). All triple-negative tumors (n = 38) had a poor prognosis-signature. Within the non triple-negative subgroup, the response of the primary tumor remained associated with the classification of the prognosis-signature (P = 0.023). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy.

AB - The 70-gene signature (MammaPrint™) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II-III patients prior to neoadjuvant chemotherapy and classified the prognosis-signatures. Pathological complete remission (pCR) was used to measure chemosensitivity. Among 167 patients, 144 (86%) were having a poor and 23 (14%) a good prognosis-signature. None of the good prognosis-signature patients achieved a pCR (0/23), whereas 29/144 patients (20%) in the poor prognosis-signature group did (P = 0.015). All triple-negative tumors (n = 38) had a poor prognosis-signature. Within the non triple-negative subgroup, the response of the primary tumor remained associated with the classification of the prognosis-signature (P = 0.023). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy.

KW - Breast cancer

KW - Chemosensitivity

KW - Gene expression signature

KW - Neoadjuvant

KW - Predictive

UR - https://www.scopus.com/pages/publications/74849111553

U2 - 10.1007/s10549-009-0333-1

DO - 10.1007/s10549-009-0333-1

M3 - Article

C2 - 19214742

AN - SCOPUS:74849111553

SN - 0167-6806

VL - 119

SP - 551

EP - 558

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 3

ER -

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit